Jackie Fouse, Agios
Agios pivots away from oncology, auctioning off cancer pipeline for $2B and shifting the spotlight in restructuring
Agios made its name as a cancer drug developer under the legendary founder David Schenkein, who took the company from a famously blank sheet of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.